ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Jul 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
September 2026
Nuclear Technology
August 2026
Fusion Science and Technology
Latest News
Texas A&M welcomes uranium conversion research
The Texas A&M Engineering Experiment Station (TEES) has signed a research agreement with Quantum Leap Energy (QLE) “to advance and de-risk the commercial production of high-purity uranium hexafluoride (UF6).”
QLE is an Austin, Texas–based subsidiary of ASP Isotopes (ASPI), which is developing an isotope enrichment platform for applications in nuclear energy, nuclear medicine, and semiconductors. QLE specializes in the uranium conversion step of the nuclear fuel cycle—the conversion of yellowcake uranium concentrate (U3O8) into UF6 prior to enrichment.
Tae Young Kong, Gamal Akabani, John W. Poston, Sr.
Nuclear Technology | Volume 205 | Number 6 | June 2019 | Pages 781-789
Technical Paper | doi.org/10.1080/00295450.2018.1546536
Articles are hosted by Taylor and Francis Online.
The 2007 Recommendation of the International Commission on Radiological Protection [ICRP Publication 103, Elsevier (2007)] requires implementation of the concept of a dose constraint for members of the public living around nuclear facilities. Under the paradigm of regulatory science, the use of dose constraints is still highly debatable. This study determines whether a dose constraint is necessary for members of the public living near U.S. nuclear power plants (NPPs) using data from the years 2007 to 2009, which were provided by the Nuclear Regulatory Commission. As a result of analysis of exposure data, it is concluded that a dose constraint is not necessary for members of the public living around U.S. NPPs and that such a constraint may place an unnecessary regulatory burden on the licensees.